Physician profile
Phuong Ho
NPI 1811179443
$13,903.05
in general payments reported to CMS, 2019-2025
35 companies · $3,998 in 2025
The $3,998 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $210 · 2021: $1,225 · 2022: $2,294 · 2023: $2,999 · 2024: $2,981 · 2025: $3,998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,674 · Education: $303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,674.43 |
| Education | $302.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,824.58 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $2,196.85 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $1,596.37 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,409.87 | 2021-2025 | Dupixent |
| Amgen INC. | $722.66 | 2022-2025 | Tezspire |
| Mallinckrodt Hospital Products INC. | $540.37 | 2021-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $431.51 | 2019-2024 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Takeda Pharmaceuticals U.S.A., INC. | $417.46 | 2021-2025 | Glassia |
| Actelion Pharmaceuticals US, INC. | $346.84 | 2021-2025 | Opsumit, Uptravi |
| Grifols USA, LLC | $318.86 | 2021-2025 | Prolastin-C Liquid, Xembify |
| Verona Pharma, INC. | $280.00 | 2025 | Ohtuvayre |
| Inspire Medical Systems, INC. | $243.50 | 2023-2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $163.49 | 2022-2025 | |
| Mylan Specialty L.P. | $157.43 | 2019-2023 | Yupelri |
| Insmed, INC. | $155.40 | 2022-2025 | Arikayce, Brinsupri |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $109.52 | 2023-2025 | Tyvaso, Tyvaso |
| Ani Pharmaceuticals, INC. | $103.86 | 2022 | |
| Merck Sharp & Dohme LLC | $94.80 | 2023-2025 | Winrevair, Keytruda |
| Novartis Pharmaceuticals Corporation | $93.58 | 2021-2023 | |
| Lilly USA, LLC | $85.63 | 2025 | Zepbound |
| Vifor Pharma, INC. | $80.25 | 2024-2025 | Zemaira |
| Electromed, INC. | $74.32 | 2022-2025 | Smartvest |
| Baxter Healthcare | $73.25 | 2022-2023 | Hillrom - Vest System Model 105 Home Care |
| Paratek Pharmaceuticals, INC. | $64.63 | 2022-2023 | Nuzyra |
| Viatris Specialty LLC | $60.83 | 2025 | Yupelri |
| Pfizer INC. | $46.97 | 2023-2024 | |
| Gilead Sciences, INC. | $41.86 | 2022 | |
| Pulmonx Corporation | $31.39 | 2022-2023 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Chartis Catheter |
| Resmed Corp | $24.09 | 2024 | |
| Azurity Pharmaceuticals, INC. | $22.66 | 2025 | Alvesco |
| Genentech USA, INC. | $22.23 | 2021 | |
| Harmony Biosciences LLC | $20.65 | 2021 | |
| Sunovion Pharmaceuticals INC. | $19.22 | 2019 | |
| Biomerieux INC | $15.28 | 2021 | |
| Foundation Medicine, INC. | $12.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phuong Ho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.